Abstract: A method of testing for an analyte in an individual comprises providing colour information obtained from a digital image of a coloured reagent on an analyte test strip, the coloured reagent having been generated in accordance with analyte in a test sample, converting the colour information from the image into an analyte level, recording the analyte level in association with user-specific information (e.g. a QR code), repeating the above steps to obtain two or more records of analyte levels for the same user at different times and using the records to monitor personal health or to predict the likely development of a disease or condition or to diagnose a disease or condition or to monitor a treatment regime associated with variation in analyte levels in saliva.

Abstract: A method of testing for an analyte in an individual comprises providing colour information obtained from a digital image of a coloured reagent on an analyte test strip, the coloured reagent having been generated in accordance with analyte in a test sample, converting the colour information from the image into an analyte level, recording the analyte level in association with user-specific information (e.g. a QR code), repeating the above steps to obtain two or more records of analyte levels for the same user at different times and using the records to monitor personal health or to predict the likely development of a disease or condition or to diagnose a disease or condition or to monitor a treatment regime associated with variation in analyte levels in saliva.

Abstract: A method of diagnosing or monitoring foetal distress comprises measuring uric acid levels in saliva in samples obtained from the expectant mother. The method provides a warning sign of complications in pregnancy such as HELLP syndrome, eclampsia, gestational diabetes, gestational hypertension, premature amniorrhexis, placenta accreta and intrauterine growth restriction. The diagnosis can be carried out in patients free from pre-eclampsia or eclampsia.